Tisento Therapeutics today announced that the global Phase 2b PRIZM study is fully enrolled. PRIZM is evaluating zagociguat – a once-daily, oral investigational medicine – as a treatment for the rare ...
Company on track to report ELEVATE-44-201 data from the first cohort in Q2 2026 and ELEVATE-45-201 data from the first cohort in mid-2026 –-- ...
Summit Royalties Ltd. (the "Corporation" or "Summit") is pleased to provide a corporate update for 2025 and highlight upcoming 2026 catalysts. All amounts in US$ unless otherwise noted. Drew Clark, ...
High school is a period of life that most of us have experienced at some point in the past, present, or future. And while it ...
Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 5 undervalued ...
Company on track to report ELEVATE-44-201 data from the first cohort in Q2 2026 and ELEVATE-45-201 data from the first cohort in mid-2026 - -- Expects to initiate global Phase 1/2 MAD clinical study ...
Approval permits the full operation of the Turmalina Mine and the plant, including the paste fill plant TORONTO, ON / ACCESS Newswire / January 7, 2026 / Jaguar Mining Inc. ("Jaguar" or the "Company") ...
El Mundo on MSNOpinion
Laurent Richard: "We are witnessing the normalization of the assassination of journalists"
The French journalist, recognized in the 'Press Freedom' category, founded Forbidden Stories eight years ago, a consortium to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback